TickerFacts.

Immucell Corp (ICCC): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2016-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$1.22M
Year ended 2025-12-31
$4.21M
Trailing 12 months to 2026-06-30
2009-12-31: -$569.2K2010-12-31: -$925.2K2011-12-31: -$281.1K2012-12-31: $69.0K2013-12-31: $501.0K2014-12-31: -$1.23M2015-12-31: $181.0K2016-12-31: -$3.81M2017-12-31: -$16.58M2018-12-31: -$2.40M2019-12-31: -$1.16M2020-12-31: -$2.76M2021-12-31: -$1.65M2022-12-31: -$5.52M2023-12-31: -$6.57M2024-12-31: -$107.8K2025-12-31: $1.22M$1.22M
2009-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31$1.22Mn/m2026-03-30, From 2025-01-01
2024-12-31-$107.8Kn/m2026-03-30, From 2024-01-01
2023-12-31-$6.57Mn/m2025-03-28, From 2023-01-01
2022-12-31-$5.52Mn/m2024-04-01, From 2022-01-01
2021-12-31-$1.65Mn/m2023-03-29, From 2021-01-01
2020-12-31-$2.76Mn/m2022-03-30, From 2020-01-01
2019-12-31-$1.16Mn/m2021-03-30, From 2019-01-01
2018-12-31-$2.40Mn/m2020-03-27, From 2018-01-01
2017-12-31-$16.58Mn/m2019-03-22, From 2017-01-01
2016-12-31-$3.81Mn/c2018-03-29, From 2016-01-01
2015-12-31$181.0Kn/m2017-03-30, From 2015-01-01
2014-12-31-$1.23Mn/m2016-03-25, From 2014-01-01
2013-12-31$501.0K+626.1%2016-03-25, From 2013-01-01
2012-12-31$69.0Kn/m2015-03-26, From 2012-01-01
2011-12-31-$281.1Kn/m2014-03-26, From 2011-01-01
2010-12-31-$925.2Kn/m2013-03-28, From 2010-01-01
2009-12-31-$569.2Kn/a2012-03-27, From 2009-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Immucell Corp (ICCC)2025-12-31$1.22Mn/m
Alpha Teknova, Inc. (TKNO)2025-12-31-$9.79Mn/m
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$395.87Mn/m
Aspira Women's Health Inc. (AWHL)2025-12-31-$7.04Mn/m
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$25.37Mn/m
Volitionrx Ltd (VNRX)2025-12-31-$19.77Mn/m
Celldex Therapeutics, Inc. (CLDX)2025-12-31-$213.66Mn/m
Neogen Corp (NEOG)2026-05-31$31.90Mn/m
QuidelOrtho Corp (QDEL)2025-12-28-$83.00Mn/m

Compare ICCC, TKNO, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗